Eprosartan MesylateThird Party Manufacturing in India

Eprosartan Mesylate is a potent, selective angiotensin II receptor blocker (ARB) that exerts its antihypertensive effect by inhibiting the renin-angiotensin-aldosterone system (RAAS). It competitively and selectively blocks the binding of angiotensin II to the angiotensin II type 1 (AT1) receptor, which is found in vascular smooth muscle, adrenal gland, and other tissues. Angiotensin II is a powerful vasoconstrictor that also stimulates aldosterone secretion, promotes sodium and water retention, and activates sympathetic nervous system activity. By occupying the AT1 receptor, eprosartan prevents angiotensin II from exerting these effects, leading to vasodilation of both resistance and capacitance vessels, reduced peripheral vascular resistance, and lower blood pressure. Unlike some other ARBs, eprosartan has a unique non-biphenyl, non-tetrazole structure that gives it a distinct binding profile with rapid association and dissociation kinetics at the AT1 receptor. It also blocks angiotensin II receptors on sympathetic nerve endings, reducing norepinephrine release and further contributing to blood pressure lowering. Eprosartan does not inhibit ACE (kininase II) and therefore does not affect bradykinin metabolism, resulting in a lower incidence of cough compared to ACE inhibitors. The drug has no partial agonist activity at the AT1 receptor and its affinity for the AT1 receptor is approximately 1,000 times greater than for the AT2 receptor.

Therapeutic Uses

Eprosartan Mesylate is prescribed for the treatment of:

• Essential Hypertension: Indicated for the management of mild to moderate essential hypertension, either alone or in combination with other antihypertensive agents such as thiazide diuretics or calcium channel blockers.
• Hypertension in Patients with Metabolic Syndrome: Eprosartan is particularly suitable for hypertensive patients with diabetes or metabolic syndrome because ARBs have beneficial effects on insulin sensitivity and do not adversely affect glucose or lipid metabolism.
• Hypertension with Left Ventricular Hypertrophy: By blocking angiotensin II-mediated cardiac remodelling, eprosartan may help prevent or regress left ventricular hypertrophy.
• Prevention of Cardiovascular Events: Long-term therapy with eprosartan reduces the risk of stroke and cardiovascular events in high-risk hypertensive patients.

Why Manufacturers Choose Eprosartan Mesylate

Eprosartan Mesylate is an important ARB molecule in the Indian antihypertensive market, available in 300 mg, 400 mg, and 600 mg tablet strengths. Indian manufacturers are well-positioned to produce cost-effective generic versions of this molecule, which has a well-established safety profile and proven efficacy. The API manufacturing process is well-characterized, and the molecule offers opportunities for combination products with hydrochlorothiazide. With growing awareness of hypertension and increasing treatment rates in India, the demand for affordable ARB therapies continues to rise. This makes Eprosartan Mesylate one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.